Weiping Qin, MD, PhD

Dr. Weiping Qin’s research focuses on developing innovative therapeutic strategies to treat skeletal and neurological impairments associated with spinal cord injury (SCI). His work integrates approaches from molecular biology, neuroscience, and regenerative medicine to elucidate how injury-induced changes in signaling pathways and inflammation contribute to tissue degeneration.

Qin has used preclinical animal models to study severe skeletal health problems associated with SCI. The research focuses include developing novel pharmacological and non-pharmacological interventions [e.g., sclerostin antibodies (Ab), Siglec-15 Ab, androgens, vibration, and electrical stimulation]. One particular interest is to study osteocyte functions.

Qin has developed a novel cutting-edge nanomedicine approach for targeted delivery as effective and safe therapeutics for neuroprotection and functional recovery after acute SCI.

Qin’s recent work uncovers a novel mechanism underlying muscle-bone communication on maintain homeostasis of the local musculoskeletal environment through osteocytes by the generation and release exosomes that encapsulate miR-218.